Kodiak Sciences Inc. (NYSE:KOD) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $15.24 and last traded at $15.24, with a volume of 14689 shares traded. The stock had previously closed at $14.05.
A number of equities analysts have recently issued reports on KOD shares. Zacks Investment Research downgraded Kodiak Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Chardan Capital reissued a “buy” rating and set a $22.50 price target on shares of Kodiak Sciences in a research report on Thursday, June 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $17.50.
The business has a 50-day moving average price of $11.76 and a 200-day moving average price of $9.84.
Kodiak Sciences (NYSE:KOD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02).
Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Kodiak Sciences during the first quarter valued at about $66,000. JPMorgan Chase & Co. boosted its position in Kodiak Sciences by 179.7% during the second quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock valued at $73,000 after purchasing an additional 4,161 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in Kodiak Sciences during the first quarter valued at about $73,000. Deutsche Bank AG bought a new stake in Kodiak Sciences during the fourth quarter valued at about $87,000. Finally, Hillsdale Investment Management Inc. bought a new stake in Kodiak Sciences during the second quarter valued at about $99,000.
Kodiak Sciences Company Profile (NYSE:KOD)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Recommended Story: Short Selling
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.